Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Express Scripts Holding Company (ESRX): This Company’s Widening Moat Swallows Competitors

Rare is it for a company to push around the likes of Walgreen Company (NYSE:WAG) and CVS Caremark Corporation (NYSE:CVS), but that is just what Express Scripts Holding Company (NASDAQ:ESRX) is managing to do.

The massive pharmacy benefit manager ended a year-long standoff with Express Scripts Holding Company (NASDAQ:ESRX) coming out ahead while Walgreen Company (NYSE:WAG) suffered irreversible damage. Meanwhile, CVS Caremark Corporation (NYSE:CVS) is quaking in its boots as it is now the last remaining giant for Express Scripts to topple. Investors who buy now may do very well for themselves as Express Scripts continues to widen its moat.

Express Scripts Holding Company

Enemy under siege

Express Scripts Holding Company (NASDAQ:ESRX) held off renewing its contract with Walgreen for nearly a year over a pricing disagreement. The result? Walgreen lost billions in revenue, not to mention the permanent loss of thousands of customers that now get their prescriptions filled at other pharmacies, while Express Scripts hardly suffered a scratch. This is evidence of significant bargaining power that is likely to persist over the coming decades.

Walgreen is no pushover; as the nation’s largest drugstore chain, it expected to have significant bargaining power in its negotiations with Express Scripts Holding Company (NASDAQ:ESRX). However, it turns out that Express Scripts can easily switch its customers to other pharmacies, a miscalculation that revealed a gaping hole in Walgreen’s moat. It is now clear that drug stores have little in the way of bargaining power when it comes to negotiations with Express Scripts.

CVS’ last stand

After the departure of less-committed pharmacy benefit managers, CVS is the last remaining major company with a significant presence in the market, save for Express Scripts Holding Company (NASDAQ:ESRX). CVS’s strategy is unique in that it seeks to leverage an integrated offering — clinical services, retail pharmacy, and pharmacy benefit management — that Express Scripts cannot match.

The idea of building an integrated system that captures 100% of a pharmacy customer’s business is alluring, but it has not worked so well for CVS. The expected synergies between the three components have yet to develop, which has caused the pharmacy benefit management segment’s margins to plummet. If CVS is unable to make its integrated offering successful, it too will fall prey to Express Scripts’ superior bargaining power.

Digging a wider moat

Even as it has its way with drugstore giants, Express Scripts is not done expanding its moat. Its 2012 acquisition of Medco enabled the company to top the 100 million member mark — members that account for about one-third of pharmaceutical spending in the United States. With these numbers in mind, it is hard to see how any pharmacy could deny concessions to Express Scripts without suffering mightily for it.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.